CD38 and Miyoshi myopathy: In conclusion, strategies aiming to optimise induction regimens—potentially through the use of anti-CD38 monoclonal antibodies—and MRD-guided treatment personalization could improve long-term outcomes in MM patients undergoing ASCT.